Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talampanel

Next Previous
Drug Profile

Talampanel

Alternative Names: GYKI-53773; LY-300164

Latest Information Update: 25 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IVAX Drug Research Institute
  • Developer Teva Pharmaceutical Industries
  • Class Antiepileptic drugs; Antineoplastics; Neuroprotectants; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Dyskinesias; Epilepsy; Glioblastoma; Multiple sclerosis

Most Recent Events

  • 23 Jun 2010 Discontinued - Phase-II for Glioblastoma in USA (PO)
  • 08 Jun 2010 Teva Pharmaceutical Industries terminates phase II trial [NCT00982150] in Amyotrophic Lateral Sclerosis in the USA, Canada, EU and Israel
  • 18 May 2010 Interim efficacy and adverse event data from a phase II trial in Amyotrophic lateral sclerosis released by Teva

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top